4.43
price up icon4.24%   0.18
after-market After Hours: 4.44 0.01 +0.23%
loading
Humacyte Inc stock is traded at $4.43, with a volume of 2.01M. It is up +4.24% in the last 24 hours and down -12.62% over the past month.
See More
Previous Close:
$4.25
Open:
$4.25
24h Volume:
2.01M
Relative Volume:
0.67
Market Cap:
$570.00M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-5.092
EPS:
-0.87
Net Cash Flow:
$-75.59M
1W Performance:
+0.68%
1M Performance:
-12.62%
6M Performance:
-33.58%
1Y Performance:
+69.73%
1-Day Range:
Value
$4.245
$4.44
1-Week Range:
Value
$4.175
$4.645
52-Week Range:
Value
$2.4512
$9.97

Humacyte Inc Stock (HUMA) Company Profile

Name
Name
Humacyte Inc
Name
Phone
919-313-9633
Name
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
HUMA's Discussions on Twitter

Compare HUMA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HUMA
Humacyte Inc
4.43 570.00M 0 -110.78M -75.59M -1.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
463.98 119.49B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
754.26 82.89B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
624.96 37.37B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.72 32.85B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
114.70 27.50B 3.30B -501.07M 1.03B -2.1146

Humacyte Inc Stock (HUMA) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-11-23 Initiated H.C. Wainwright Buy
Aug-14-23 Upgrade Piper Sandler Underweight → Neutral
Jun-22-23 Initiated Cantor Fitzgerald Overweight
May-16-22 Downgrade Piper Sandler Overweight → Underweight
Oct-29-21 Initiated Cowen Outperform
Sep-24-21 Initiated Oppenheimer Outperform
Sep-22-21 Initiated BTIG Research Buy
Sep-16-21 Initiated Piper Sandler Overweight
View All

Humacyte Inc Stock (HUMA) Latest News

pulisher
04:19 AM

Humacyte director Michael Constantino purchases $20,181 in stock - Investing.com India

04:19 AM
pulisher
04:15 AM

Humacyte director Michael Constantino purchases $20,181 in stock By Investing.com - Investing.com Australia

04:15 AM
pulisher
12:42 PM

The Gross Law Firm Announces the Filing of a Securities - GlobeNewswire

12:42 PM
pulisher
12:10 PM

DEADLINE ALERT for HUMA, XRX, and ZETA: The Law Offices of - GlobeNewswire

12:10 PM
pulisher
03:17 AM

Thrivent Financial for Lutherans Acquires New Shares in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat

03:17 AM
pulisher
Dec 03, 2024

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, - GlobeNewswire

Dec 03, 2024
pulisher
Dec 03, 2024

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel - The Bakersfield Californian

Dec 03, 2024
pulisher
Dec 03, 2024

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Dec 03, 2024
pulisher
Dec 03, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Humacyte, Inc.- HUMA - PR Newswire

Dec 03, 2024
pulisher
Dec 03, 2024

Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire

Dec 03, 2024
pulisher
Dec 03, 2024

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - GlobeNewswire

Dec 03, 2024
pulisher
Dec 03, 2024

Humacyte, Inc. Class Action Lawsuit Alert: Johnson Fistel - GlobeNewswire

Dec 03, 2024
pulisher
Dec 03, 2024

Robbins LLP Urges HUMA Stockholders with Large Losses to - GlobeNewswire

Dec 03, 2024
pulisher
Dec 02, 2024

Kirby McInerney LLP Reminds Humacyte (HUMA) Investors of Class Action Filing and Encourages Investors to Contact the Firm - Business Wire

Dec 02, 2024
pulisher
Dec 02, 2024

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - PR Newswire

Dec 02, 2024
pulisher
Dec 02, 2024

Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire

Dec 02, 2024
pulisher
Dec 02, 2024

HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein - GlobeNewswire

Dec 02, 2024
pulisher
Dec 02, 2024

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times

Dec 02, 2024
pulisher
Dec 02, 2024

Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - PR Newswire

Dec 02, 2024
pulisher
Nov 30, 2024

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel - The Bakersfield Californian

Nov 30, 2024
pulisher
Nov 30, 2024

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, - GlobeNewswire

Nov 30, 2024
pulisher
Nov 30, 2024

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Nov 30, 2024
pulisher
Nov 29, 2024

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Markets Insider

Nov 29, 2024
pulisher
Nov 29, 2024

HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Nov 29, 2024
pulisher
Nov 29, 2024

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Lelezard

Nov 29, 2024
pulisher
Nov 27, 2024

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Humacyte, Inc. Investors to Secure - The Bakersfield Californian

Nov 27, 2024
pulisher
Nov 27, 2024

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Nov 27, 2024
pulisher
Nov 27, 2024

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - Benzinga

Nov 27, 2024
pulisher
Nov 27, 2024

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - AccessWire

Nov 27, 2024
pulisher
Nov 27, 2024

Finansavisen - Finansavisen

Nov 27, 2024
pulisher
Nov 26, 2024

Kirby McInerney LLP Reminds Humacyte, Inc. (HUMA) Investors - GlobeNewswire

Nov 26, 2024
pulisher
Nov 26, 2024

The Gross Law Firm Reminds Humacyte, Inc. Investors of the - GlobeNewswire

Nov 26, 2024
pulisher
Nov 26, 2024

HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Nov 26, 2024
pulisher
Nov 26, 2024

HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire

Nov 26, 2024
pulisher
Nov 26, 2024

HUMA LAWSUIT ALERT: Levi Korsinsky Notifies Humacyte, Inc. | Trending From Our Network - Chicago Star Media

Nov 26, 2024
pulisher
Nov 26, 2024

HUMA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire

Nov 26, 2024
pulisher
Nov 25, 2024

HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire

Nov 25, 2024
pulisher
Nov 25, 2024

Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues – Hagens Berman - GlobeNewswire

Nov 25, 2024
pulisher
Nov 25, 2024

Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat

Nov 25, 2024
pulisher
Nov 24, 2024

HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire

Nov 24, 2024
pulisher
Nov 24, 2024

Humacyte, Inc. (NASDAQ:HUMA) Receives $11.00 Average Target Price from Analysts - MarketBeat

Nov 24, 2024
pulisher
Nov 24, 2024

Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action - GlobeNewswire

Nov 24, 2024
pulisher
Nov 23, 2024

HUMA DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before January 17, 2025 - The Globe and Mail

Nov 23, 2024
pulisher
Nov 22, 2024

Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead - The Bakersfield Californian

Nov 22, 2024
pulisher
Nov 22, 2024

Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – HUMA - Morningstar

Nov 22, 2024
pulisher
Nov 22, 2024

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) - The Manila Times

Nov 22, 2024
pulisher
Nov 22, 2024

Humacyte sees success in dual emergency-engineered tissue trials - Yahoo Finance

Nov 22, 2024
pulisher
Nov 22, 2024

HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire

Nov 22, 2024
pulisher
Nov 22, 2024

The Gross Law Firm Announces the Filing of a Securities Class Ac - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - Marketscreener.com

Nov 22, 2024

Humacyte Inc Stock (HUMA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.65
price down icon 0.23%
$74.62
price up icon 3.60%
$41.63
price down icon 2.23%
$374.40
price up icon 1.52%
$199.09
price down icon 3.36%
$114.70
price down icon 0.77%
Cap:     |  Volume (24h):